PanGenomic Health Appoints Manpreet Dhillon as Director, Names New CFO, and Announces Proceeds from Warrant Exercise

Vancouver, British Columbia — July 11, 2025 — NewsWall — PanGenomic Health Inc. (CSE: NARA) has appointed Manpreet Dhillon as a director.

Ms. Dhillon brings over 20 years of international consulting experience, specializing in economic empowerment, gender equality, and stakeholder engagement for international non-governmental organizations and governments within the United Nations system. She is also the founder of Veza Global, which provides solutions to support employers in addressing diversity, equity, inclusion, and belonging.

PanGenomic Health also announced the resignation of Francisco Kent Carasquero as a director and Chief Financial Officer, effective immediately. Tammy Gillis, a current financial consultant who previously served as CFO, has assumed the position. Ms. Gillis is a CPA, CMA with over 20 years' experience in the public markets and brings a comprehensive background in finance, reporting and regulatory requirements for junior exploration, manufacturing, bio-technology, and technology industries.

The company has received approximately $731,000 in proceeds from the exercise of 4,300,464 share purchase warrants issued in May 2024 and repriced to $0.17 per share on January 29, 2025. The proceeds will be used for general working capital purposes.

Additionally, the Board of Directors has granted stock options representing 1,350,000 common shares to officers and directors of the company. The options were granted at an exercise price of $1.15, vest in equal quarterly installments over one year, and expire on July 11, 2028.

Jerry Lai, Investor Relations PanGenomic Health Inc. +1 778 743 4642 ir@pangenomic.com

Fairfax Partners Inc. Daniel Southan-Dwyer, President +1 604 366 6277 connect@fairfaxpartners.ca

Source: PanGenomic Health